Abdallah Safawi

Abdallah Safawi

Auto-generated profile, based on publicly available information

Abdallah Safawi

Faculty of Medical Sciences, Lebanese University, Hadath, Lebanon

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2025 in Medical Gas Research
Verified
Journal Article
Open access
ABAbbas Al Bazzal
Abbas Al Bazzal
BHBassel H. Hoteit
Bassel H. Hoteit
MCMariam Chokor
Mariam Chokor
ASAbdallah Safawi
Abdallah Safawi
ZZZahraa Zibara
Zahraa Zibara
HHHiba Hamdar
Hiba Hamdar
Medical gases were primarily used for respiratory therapy and anesthesia, which showed promising potential in the cancer therapy. Several physiological and pathological processes were affected by the key gases, such as oxygen, carbon dioxide, nitric oxide, hydrogen sulfide, and carbon monoxide. Oxygen targets shrinking the tumor via hyperbaric oxygen therapy, and once combined with radiation therapy it enhances its effect. Nitric oxide has both anti- and pro-tumor effects depending on its level; at high doses, it triggers cell death while at low doses it supports cancer growth. The same concept is applied to hydrogen sulfide which promotes cancer growth by enhancing mitochondrial bioenergetics and supporting angiogenesis at low concentrations, while at high concentrations it induces cancer cell death while sparing normal cells. Furthermore, carbon dioxide helps induce apoptosis and improve oxygenation for cancer treatments by increasing the release of oxygen from hemoglobin. Moreover, high-dose carbon monoxide gas therapy has demonstrated significant tumor reductions in vivo and is supported by nanomedicine and specialized medicines to boost its delivery to tumor cells and the availability of hydrogen peroxide. Despite the promising potentials of these gases, several challenges remain. Gas concentrations should be regulated to balance pro-tumor and anti-tumor effects for gases such as nitric oxide and hydrogen sulfide. Furthermore, effective delivery systems, such as nanoparticles, should be developed for targeted therapy.

7 October 2025 in Therapeutic Advances in Endocrinology and Metabolism
Verified
Journal Article
Open access
BHBassel H. Hoteit
Bassel H. Hoteit
JKJana Kotaich
Jana Kotaich
HFHadi Ftouni
Hadi Ftouni
FHFatima Hazime
Fatima Hazime
ASAbdallah Safawi
Abdallah Safawi
MMMia Marwani
Mia Marwani
Polycystic ovary syndrome (PCOS) is a prevalent disorder in the modern world, affecting around 6%–20% of females of childbearing age. Hormonal and metabolic symptoms vary over time but often arise throughout puberty. Treatment includes lifestyle interventions as a first line of treatment. In certain cases, specific medications may be considered. However, there is a growing interest in using Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in PCOS due to their efficacy in weight loss, insulin resistance, and heart health. Aside from the metabolic role of GLP-1RAs, which aids in the relief of PCOS symptoms, there is also the possibility of direct involvement in reproductive health in PCOS, including its role in the hypothalamic-gonadal axis, menstrual irregularity, ovulation, ovarian morphology, anti-inflammatory properties, and fertility. This review discusses the latest data on GLP-1RAs’ metabolic and reproductive health benefits in PCOS. Moreover, this article covers pharmaceutical interactions and synergistic effects of drugs, including metformin and other medications, with GLP-1RAs. It also conveys an overview of recent clinical trials utilizing GLP-1RAs to treat PCOS.